Stay updated with breaking news from Eyepoint Durasert. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
-- RLYB212 Phase 1b Proof-of-Concept Study Results to be Presented at 31st Congress of the International Society of Thrombosis and Haemostasis in June 2023 -- -- Phase 1 Multiple Dose Cohort... | May 9, 2023
/PRNewswire/ -- EyePoint Pharmaceuticals, Inc. (NASDAQ: EYPT), a pharmaceutical company committed to developing and commercializing therapeutics to improve the...
/PRNewswire/ -- EyePoint Pharmaceuticals, Inc. (NASDAQ: EYPT), a pharmaceutical company committed to developing and commercializing therapeutics to improve the...